While the maintenance of a Buy rating suggests continued confidence in Mirum Pharmaceuticals' fundamentals and future prospects, the reduction in the price target could indicate concerns about near-term challenges or valuation adjustments. This mixed signal might lead to short-term market uncertainty for MIRM's stock, but the overall positive stance could mitigate significant negative impact.